Liver injury associated with the B-interferons for MS Liver injury associated with the B-interferons for MS2018-01-17T17:01:53-05:00
Interferons in relapsing remitting multiple sclerosis: a systematic review Interferons in relapsing remitting multiple sclerosis: a systematic review2018-01-17T17:01:53-05:00
Future Immunotherapies in Multiple Sclerosis Future Immunotherapies in Multiple Sclerosis2018-01-17T17:01:53-05:00
Transdermal Histamine in Multiple Sclerosis, Part Two: A Proposed Theoretical Basis for Its Use. Transdermal Histamine in Multiple Sclerosis, Part Two: A Proposed Theoretical Basis for Its Use.2018-01-17T17:01:47-05:00
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn’s Disease Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn’s Disease2018-01-17T17:01:47-05:00
Immunotherapies: cause for measured optimism Immunotherapies: cause for measured optimism2018-01-17T17:01:47-05:00
When marketing and science intersect: Do patients with MS benefit? When marketing and science intersect: Do patients with MS benefit?2018-01-17T17:01:42-05:00
